Literature DB >> 14560040

Subtype-selective up-regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography.

Henry N Nguyen1, Bruce A Rasmussen, David C Perry.   

Abstract

Subtypes of neuronal nicotinic acetylcholine receptors (nAChRs) are differentially sensitive to up-regulation by chronic nicotine exposure in vitro. To determine whether this occurs in animals, rats were implanted with minipumps containing saline +/- nicotine (6.0 mg/kg/rat/day) for 14 days. Autoradiography with [125I]epibatidine using 3-(2(S)-azetidinylmethoxy)pyridine dihydrochloride (A-85380) or cytisine as selective competitors allowed quantitative measurement in 33 regions of 3 families of nAChR binding, with properties of alpha4beta2, alpha3beta4, and alpha3/alpha6beta2. Chronic nicotine exposure caused increases of 20 to 100% for alpha4beta2-like binding in most regions surveyed. However, binding to this subtype was not increased in some regions, including habenulopeduncular structures, certain thalamic nuclei, and several brainstem regions. In 9 of 33 regions, including catecholaminergic areas and visual structures, alpha3/alpha6beta2-like binding represented >10% of total binding. Binding to this subtype was up-regulated by nicotine in only two of these nine regions: the nucleus accumbens and superior colliculus. alpha3beta4-Like binding represented >10% of total in 15 of the 33 regions surveyed. Binding to this subtype was increased by nicotine in only 1 of these 15 regions, and actually decreased in subiculum and cerebellum. These studies yielded two principal findings. First, chronic nicotine exposure selectively up-regulates alpha4beta2-like binding, with relatively little effect on alpha3/alpha6beta2-like and alpha3beta4-like binding in vivo. Second, up-regulation by chronic nicotine exposure shows considerable regional variation. Differential subtype sensitivity to chronic nicotine exposure may contribute to altered pharmacological response in individuals who smoke or use nicotine replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14560040     DOI: 10.1124/jpet.103.056408

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  65 in total

1.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

2.  Regulation of the distribution and function of [(125)I]epibatidine binding sites by chronic nicotine in mouse embryonic neuronal cultures.

Authors:  Cristian A Zambrano; Rakel M Salamander; Allan C Collins; Sharon R Grady; Michael J Marks
Journal:  J Pharmacol Exp Ther       Date:  2012-04-24       Impact factor: 4.030

Review 3.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

4.  The effects of lobeline on nicotine withdrawal-induced depression-like behavior in mice.

Authors:  Monzurul Amin Roni; Shafiqur Rahman
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

5.  Role of α7- and β4-containing nicotinic acetylcholine receptors in the affective and somatic aspects of nicotine withdrawal: studies in knockout mice.

Authors:  Astrid K Stoker; Berend Olivier; Athina Markou
Journal:  Behav Genet       Date:  2011-10-19       Impact factor: 2.805

6.  Regulation of α4β2α5 nicotinic acetylcholinergic receptors in rat cerebral cortex in early and late adolescence: Sex differences in response to chronic nicotine.

Authors:  Bethany G Hoegberg; Ermelinda Lomazzo; Norman H Lee; David C Perry
Journal:  Neuropharmacology       Date:  2015-08-10       Impact factor: 5.250

7.  Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning.

Authors:  Jennifer A Davis; Thomas J Gould
Journal:  Neuropsychopharmacology       Date:  2007-01-17       Impact factor: 7.853

Review 8.  Inside-out neuropharmacology of nicotinic drugs.

Authors:  Brandon J Henderson; Henry A Lester
Journal:  Neuropharmacology       Date:  2015-02-04       Impact factor: 5.250

9.  Single photon emission computed tomography experience with (S)-5-[(123)I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers.

Authors:  James Robert Brasić; Yun Zhou; John L Musachio; John Hilton; Hong Fan; Andrew Crabb; Christopher J Endres; Melvin J Reinhardt; Ahmet S Dogan; Mohab Alexander; Olivier Rousset; Marika A Maris; Jeffrey Galecki; Ayon Nandi; Dean F Wong
Journal:  Synapse       Date:  2009-04       Impact factor: 2.562

10.  Differential effects of withdrawal from intermittent and continuous nicotine exposure on reward deficit and somatic aspects of nicotine withdrawal and expression of α4β2* nAChRs in Wistar male rats.

Authors:  Svetlana Semenova; Xinchun Jin; Tristan D McClure-Begley; Matthew Philip Tadman; Michael J Marks; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2018-06-14       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.